PMC:7029452 / 17742-25251
Annnotations
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"280","span":{"begin":132,"end":142},"obj":"Species"},{"id":"281","span":{"begin":907,"end":911},"obj":"Species"},{"id":"282","span":{"begin":20,"end":28},"obj":"Disease"},{"id":"283","span":{"begin":187,"end":195},"obj":"Disease"},{"id":"284","span":{"begin":429,"end":448},"obj":"Disease"},{"id":"285","span":{"begin":810,"end":820},"obj":"Disease"},{"id":"286","span":{"begin":889,"end":893},"obj":"Disease"},{"id":"287","span":{"begin":919,"end":937},"obj":"Disease"},{"id":"297","span":{"begin":1610,"end":1618},"obj":"Species"},{"id":"298","span":{"begin":1623,"end":1631},"obj":"Species"},{"id":"299","span":{"begin":1253,"end":1284},"obj":"Disease"},{"id":"300","span":{"begin":1427,"end":1447},"obj":"Disease"},{"id":"301","span":{"begin":1591,"end":1599},"obj":"Disease"},{"id":"302","span":{"begin":1761,"end":1780},"obj":"Disease"},{"id":"303","span":{"begin":1962,"end":1970},"obj":"Disease"},{"id":"304","span":{"begin":2131,"end":2162},"obj":"Disease"},{"id":"305","span":{"begin":2362,"end":2370},"obj":"Disease"},{"id":"307","span":{"begin":2893,"end":2901},"obj":"Disease"},{"id":"311","span":{"begin":3341,"end":3348},"obj":"Species"},{"id":"312","span":{"begin":3860,"end":3867},"obj":"Species"},{"id":"313","span":{"begin":3673,"end":3692},"obj":"Disease"},{"id":"318","span":{"begin":3964,"end":3974},"obj":"Species"},{"id":"319","span":{"begin":3997,"end":4002},"obj":"Species"},{"id":"320","span":{"begin":4006,"end":4011},"obj":"Species"},{"id":"321","span":{"begin":4871,"end":4876},"obj":"Disease"},{"id":"323","span":{"begin":5027,"end":5037},"obj":"Species"},{"id":"326","span":{"begin":5336,"end":5346},"obj":"Species"},{"id":"327","span":{"begin":5437,"end":5446},"obj":"Disease"},{"id":"332","span":{"begin":5713,"end":5718},"obj":"Species"},{"id":"333","span":{"begin":5722,"end":5727},"obj":"Species"},{"id":"334","span":{"begin":5552,"end":5560},"obj":"Disease"},{"id":"335","span":{"begin":6066,"end":6074},"obj":"Disease"},{"id":"341","span":{"begin":6439,"end":6444},"obj":"Species"},{"id":"342","span":{"begin":6448,"end":6453},"obj":"Species"},{"id":"343","span":{"begin":6470,"end":6480},"obj":"Species"},{"id":"344","span":{"begin":6733,"end":6743},"obj":"Species"},{"id":"345","span":{"begin":6137,"end":6145},"obj":"Disease"},{"id":"348","span":{"begin":7395,"end":7405},"obj":"Species"},{"id":"349","span":{"begin":7172,"end":7180},"obj":"Disease"}],"attributes":[{"id":"A280","pred":"tao:has_database_id","subj":"280","obj":"Tax:2697049"},{"id":"A281","pred":"tao:has_database_id","subj":"281","obj":"Tax:114727"},{"id":"A282","pred":"tao:has_database_id","subj":"282","obj":"MESH:C000657245"},{"id":"A283","pred":"tao:has_database_id","subj":"283","obj":"MESH:C000657245"},{"id":"A284","pred":"tao:has_database_id","subj":"284","obj":"MESH:D003141"},{"id":"A285","pred":"tao:has_database_id","subj":"285","obj":"MESH:D007239"},{"id":"A286","pred":"tao:has_database_id","subj":"286","obj":"MESH:D018352"},{"id":"A287","pred":"tao:has_database_id","subj":"287","obj":"MESH:D019142"},{"id":"A297","pred":"tao:has_database_id","subj":"297","obj":"Tax:694009"},{"id":"A298","pred":"tao:has_database_id","subj":"298","obj":"Tax:1335626"},{"id":"A299","pred":"tao:has_database_id","subj":"299","obj":"MESH:D012120"},{"id":"A300","pred":"tao:has_database_id","subj":"300","obj":"MESH:D012818"},{"id":"A301","pred":"tao:has_database_id","subj":"301","obj":"MESH:C000657245"},{"id":"A302","pred":"tao:has_database_id","subj":"302","obj":"MESH:D003141"},{"id":"A303","pred":"tao:has_database_id","subj":"303","obj":"MESH:C000657245"},{"id":"A304","pred":"tao:has_database_id","subj":"304","obj":"MESH:D012120"},{"id":"A305","pred":"tao:has_database_id","subj":"305","obj":"MESH:C000657245"},{"id":"A307","pred":"tao:has_database_id","subj":"307","obj":"MESH:C000657245"},{"id":"A311","pred":"tao:has_database_id","subj":"311","obj":"Tax:9606"},{"id":"A312","pred":"tao:has_database_id","subj":"312","obj":"Tax:9606"},{"id":"A313","pred":"tao:has_database_id","subj":"313","obj":"MESH:D003141"},{"id":"A318","pred":"tao:has_database_id","subj":"318","obj":"Tax:2697049"},{"id":"A319","pred":"tao:has_database_id","subj":"319","obj":"Tax:9606"},{"id":"A320","pred":"tao:has_database_id","subj":"320","obj":"Tax:9606"},{"id":"A321","pred":"tao:has_database_id","subj":"321","obj":"MESH:D003371"},{"id":"A323","pred":"tao:has_database_id","subj":"323","obj":"Tax:2697049"},{"id":"A326","pred":"tao:has_database_id","subj":"326","obj":"Tax:2697049"},{"id":"A327","pred":"tao:has_database_id","subj":"327","obj":"MESH:D007239"},{"id":"A332","pred":"tao:has_database_id","subj":"332","obj":"Tax:9606"},{"id":"A333","pred":"tao:has_database_id","subj":"333","obj":"Tax:9606"},{"id":"A334","pred":"tao:has_database_id","subj":"334","obj":"MESH:C000657245"},{"id":"A335","pred":"tao:has_database_id","subj":"335","obj":"MESH:C000657245"},{"id":"A341","pred":"tao:has_database_id","subj":"341","obj":"Tax:9606"},{"id":"A342","pred":"tao:has_database_id","subj":"342","obj":"Tax:9606"},{"id":"A343","pred":"tao:has_database_id","subj":"343","obj":"Tax:2697049"},{"id":"A344","pred":"tao:has_database_id","subj":"344","obj":"Tax:2697049"},{"id":"A345","pred":"tao:has_database_id","subj":"345","obj":"MESH:C000657245"},{"id":"A348","pred":"tao:has_database_id","subj":"348","obj":"Tax:2697049"},{"id":"A349","pred":"tao:has_database_id","subj":"349","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Discussion\nSpecific COVID-19 surveillance has been in place in France since 10 January 2020, 3 days after the identification of the SARS-CoV-2 in China. The first three imported cases of COVID-19 in France, the first ones in Europe, were diagnosed 14 days later, on 24 January. Rapid and effective collaboration between the clinicians (general practitioners attending the cases, emergency hotline clinicians (SAMU-centre 15) and infectious diseases specialists), the National Reference Centre and the regional and national health authorities has played a crucial role in the system’s capacity to quickly detect, isolate and investigate those cases in order to implement adequate control measures. The surveillance system as well as the control measures were adapted from those implemented during past emerging infections that occurred after 2003 (severe acute respiratory syndrome (SARS), MERS, influenza A(H1N1)pdm09, Ebolavirus disease), and all involved parties were already familiar with the system, which probably favoured its responsiveness.\nThe case definition of a possible case in use on 24 January was slightly adapted from the one provided by the World Health Organization (WHO), based on an epidemiological link to Wuhan, China and a severe lower acute respiratory disease. It is noteworthy that the first nine possible cases identified in France, including the three confirmed cases described here, displayed mild respiratory symptoms with no sign of severity at the time of diagnosis. Increasing evidence suggests that mild clinical symptoms could be more frequent in cases of COVID-19 than with SARS-CoV and MERS-CoV [5]. Therefore, the case definition in effect on 24 January lacked sensitivity. This was counter-balanced by a tendency from the infectious diseases specialists in charge of classification of suspected cases to privilege the exposure to Wuhan over the clinical presentation in their decision. However, we cannot exclude that some COVID-19 cases remained undetected in France because of the lack of sensitivity of our case definition. The clinical criteria were expanded on 4 February to include any lower acute respiratory disease and the epidemiological criterion was extended to the whole of China. At that time, the French laboratory capacities were reinforced from one to five laboratories able to perform the diagnostics for COVID-19. Further extension to all 38 referring hospital laboratories is expected by early to mid-February 2020. Santé publique France will deploy in early February the outbreak investigation tool developed by the WHO (Go.Data [6]) in order to facilitate case data management and contact tracing at the national and local level in France.\nContact and co-exposure identification of the three confirmed cases had been initiated as soon as they were classified as possible cases, which facilitated investigations upon confirmation of COVID-19. Confirmation of the diagnosis was made in the evening of 24 January and the investigation to retrieve as exhaustively as possible contacts and co-exposed individuals and evaluate their level of risk of transmission was started immediately overnight. Complete transparency of the investigations was ensured through daily press conferences held by the French health authorities.\nAlthough the follow-up procedure for the contacts/co-exposed persons used in France slightly differ from the ECDC and WHO guidelines [7,8], which were not available at the time of this investigation, it relies on the same general principles. Contact tracing of the passengers seated near Case 1 during the two flights Shanghai–Paris and Paris–Bordeaux was adapted from the ECDC guidelines for infectious diseases transmitted on aircraft [9]. Even though Case 1 was wearing a face mask during those flights, we could not exclude breaches and subsequent risk of transmission to the persons sitting in the two seats around him.\nBecause of the current uncertainties about the capacity of SARS-CoV-2 to easily spread from human to human, the decision to consider a contact as close if the case–contact distance was between 1 m and 2 m was made on a case-by-case basis, depending on the type and length of interaction. Through the extensive interviews made with the cases and their high compliance to cooperate to the investigation, we believe that the contacts most at risk have been satisfactorily identified. All of them could be rapidly contacted and informed about measures to be taken, which they all agreed to. However, some contacts were either impossible to trace back (e.g. co-travellers on public transportation) or evaluated as at negligible risk of exposure because of short and/or distant contacts (e.g. restaurant, contacts with cashiers while running errands, visiting museums), although accidental events carrying the risk of transmission on such occasions, such as an episode of cough of sneezing, cannot be ruled out.\nMoreover, the contact tracing was limited to the period after onset of illness. However, should the transmission of SARS-CoV-2 occur during the asymptomatic phase, we cannot exclude that secondary transmission events initiated from the three confirmed cases remained undetected during the investigations.\nCase 3 developed symptoms 4 days after her husband and 5 days after the couple had left Wuhan. The incubation period of SARS-CoV-2 is currently estimated at around 3–7 days [5,10,11]. Therefore, she may have acquired the infection from her husband, although this cannot be proved.\nThe active surveillance of close contacts of confirmed COVID-19 cases and the implementation of control measures, including home quarantine for those evaluated at moderate/high risk of exposure, decrease the risk of human-to-human transmission originating from imported cases and subsequently delay propagation of the virus in the general population. This allows our healthcare system to prepare for any further spread of the epidemic. Besides, the epidemiological and clinical data collected about the confirmed cases and their contacts will increase our knowledge of COVID-19.\nThe rapid and collaborative management of the first imported COVID-19 cases in France highlights the fact that the French healthcare system is adequately prepared to respond to such emerging diseases threats. However, this surveillance system is extremely time-consuming and requires considerable manpower. The data available on 12 February strongly suggest that human-to-human transmission of SARS-CoV-2 is frequent, with the reproduction number estimated at 2 to 3 [5,10-14]. Twenty-five countries have already reported imported cases from China, and several of them have described autochthonous transmission events [15]. In the case of further spread of SARS-CoV-2 worldwide, it would soon become impossible to detect all imported cases and trace their contacts. Especially the occurrence of large clusters in the same region would strongly impact on the local health authorities’ capacities. The surveillance objectives would then need to evolve from containing the epidemic to mitigating its medical and societal impact.\nAs at 12 February, the contacts of the three first confirmed cases of COVID-19 in France have been followed up for the whole 14 days follow-up time after the cases isolation. No secondary transmission event has been detected so far despite active follow-up. Given the first estimations of the SARS-CoV-2 incubation period, the probability of secondary cases originating from those three cases is negligible."}
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T17","span":{"begin":3755,"end":3759},"obj":"Body_part"},{"id":"T18","span":{"begin":4547,"end":4551},"obj":"Body_part"}],"attributes":[{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma24728"},{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma25056"}],"text":"Discussion\nSpecific COVID-19 surveillance has been in place in France since 10 January 2020, 3 days after the identification of the SARS-CoV-2 in China. The first three imported cases of COVID-19 in France, the first ones in Europe, were diagnosed 14 days later, on 24 January. Rapid and effective collaboration between the clinicians (general practitioners attending the cases, emergency hotline clinicians (SAMU-centre 15) and infectious diseases specialists), the National Reference Centre and the regional and national health authorities has played a crucial role in the system’s capacity to quickly detect, isolate and investigate those cases in order to implement adequate control measures. The surveillance system as well as the control measures were adapted from those implemented during past emerging infections that occurred after 2003 (severe acute respiratory syndrome (SARS), MERS, influenza A(H1N1)pdm09, Ebolavirus disease), and all involved parties were already familiar with the system, which probably favoured its responsiveness.\nThe case definition of a possible case in use on 24 January was slightly adapted from the one provided by the World Health Organization (WHO), based on an epidemiological link to Wuhan, China and a severe lower acute respiratory disease. It is noteworthy that the first nine possible cases identified in France, including the three confirmed cases described here, displayed mild respiratory symptoms with no sign of severity at the time of diagnosis. Increasing evidence suggests that mild clinical symptoms could be more frequent in cases of COVID-19 than with SARS-CoV and MERS-CoV [5]. Therefore, the case definition in effect on 24 January lacked sensitivity. This was counter-balanced by a tendency from the infectious diseases specialists in charge of classification of suspected cases to privilege the exposure to Wuhan over the clinical presentation in their decision. However, we cannot exclude that some COVID-19 cases remained undetected in France because of the lack of sensitivity of our case definition. The clinical criteria were expanded on 4 February to include any lower acute respiratory disease and the epidemiological criterion was extended to the whole of China. At that time, the French laboratory capacities were reinforced from one to five laboratories able to perform the diagnostics for COVID-19. Further extension to all 38 referring hospital laboratories is expected by early to mid-February 2020. Santé publique France will deploy in early February the outbreak investigation tool developed by the WHO (Go.Data [6]) in order to facilitate case data management and contact tracing at the national and local level in France.\nContact and co-exposure identification of the three confirmed cases had been initiated as soon as they were classified as possible cases, which facilitated investigations upon confirmation of COVID-19. Confirmation of the diagnosis was made in the evening of 24 January and the investigation to retrieve as exhaustively as possible contacts and co-exposed individuals and evaluate their level of risk of transmission was started immediately overnight. Complete transparency of the investigations was ensured through daily press conferences held by the French health authorities.\nAlthough the follow-up procedure for the contacts/co-exposed persons used in France slightly differ from the ECDC and WHO guidelines [7,8], which were not available at the time of this investigation, it relies on the same general principles. Contact tracing of the passengers seated near Case 1 during the two flights Shanghai–Paris and Paris–Bordeaux was adapted from the ECDC guidelines for infectious diseases transmitted on aircraft [9]. Even though Case 1 was wearing a face mask during those flights, we could not exclude breaches and subsequent risk of transmission to the persons sitting in the two seats around him.\nBecause of the current uncertainties about the capacity of SARS-CoV-2 to easily spread from human to human, the decision to consider a contact as close if the case–contact distance was between 1 m and 2 m was made on a case-by-case basis, depending on the type and length of interaction. Through the extensive interviews made with the cases and their high compliance to cooperate to the investigation, we believe that the contacts most at risk have been satisfactorily identified. All of them could be rapidly contacted and informed about measures to be taken, which they all agreed to. However, some contacts were either impossible to trace back (e.g. co-travellers on public transportation) or evaluated as at negligible risk of exposure because of short and/or distant contacts (e.g. restaurant, contacts with cashiers while running errands, visiting museums), although accidental events carrying the risk of transmission on such occasions, such as an episode of cough of sneezing, cannot be ruled out.\nMoreover, the contact tracing was limited to the period after onset of illness. However, should the transmission of SARS-CoV-2 occur during the asymptomatic phase, we cannot exclude that secondary transmission events initiated from the three confirmed cases remained undetected during the investigations.\nCase 3 developed symptoms 4 days after her husband and 5 days after the couple had left Wuhan. The incubation period of SARS-CoV-2 is currently estimated at around 3–7 days [5,10,11]. Therefore, she may have acquired the infection from her husband, although this cannot be proved.\nThe active surveillance of close contacts of confirmed COVID-19 cases and the implementation of control measures, including home quarantine for those evaluated at moderate/high risk of exposure, decrease the risk of human-to-human transmission originating from imported cases and subsequently delay propagation of the virus in the general population. This allows our healthcare system to prepare for any further spread of the epidemic. Besides, the epidemiological and clinical data collected about the confirmed cases and their contacts will increase our knowledge of COVID-19.\nThe rapid and collaborative management of the first imported COVID-19 cases in France highlights the fact that the French healthcare system is adequately prepared to respond to such emerging diseases threats. However, this surveillance system is extremely time-consuming and requires considerable manpower. The data available on 12 February strongly suggest that human-to-human transmission of SARS-CoV-2 is frequent, with the reproduction number estimated at 2 to 3 [5,10-14]. Twenty-five countries have already reported imported cases from China, and several of them have described autochthonous transmission events [15]. In the case of further spread of SARS-CoV-2 worldwide, it would soon become impossible to detect all imported cases and trace their contacts. Especially the occurrence of large clusters in the same region would strongly impact on the local health authorities’ capacities. The surveillance objectives would then need to evolve from containing the epidemic to mitigating its medical and societal impact.\nAs at 12 February, the contacts of the three first confirmed cases of COVID-19 in France have been followed up for the whole 14 days follow-up time after the cases isolation. No secondary transmission event has been detected so far despite active follow-up. Given the first estimations of the SARS-CoV-2 incubation period, the probability of secondary cases originating from those three cases is negligible."}
LitCovid-PD-UBERON
{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T12","span":{"begin":2380,"end":2389},"obj":"Body_part"},{"id":"T13","span":{"begin":3755,"end":3759},"obj":"Body_part"}],"attributes":[{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_2000106"},{"id":"A13","pred":"uberon_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/UBERON_0001456"}],"text":"Discussion\nSpecific COVID-19 surveillance has been in place in France since 10 January 2020, 3 days after the identification of the SARS-CoV-2 in China. The first three imported cases of COVID-19 in France, the first ones in Europe, were diagnosed 14 days later, on 24 January. Rapid and effective collaboration between the clinicians (general practitioners attending the cases, emergency hotline clinicians (SAMU-centre 15) and infectious diseases specialists), the National Reference Centre and the regional and national health authorities has played a crucial role in the system’s capacity to quickly detect, isolate and investigate those cases in order to implement adequate control measures. The surveillance system as well as the control measures were adapted from those implemented during past emerging infections that occurred after 2003 (severe acute respiratory syndrome (SARS), MERS, influenza A(H1N1)pdm09, Ebolavirus disease), and all involved parties were already familiar with the system, which probably favoured its responsiveness.\nThe case definition of a possible case in use on 24 January was slightly adapted from the one provided by the World Health Organization (WHO), based on an epidemiological link to Wuhan, China and a severe lower acute respiratory disease. It is noteworthy that the first nine possible cases identified in France, including the three confirmed cases described here, displayed mild respiratory symptoms with no sign of severity at the time of diagnosis. Increasing evidence suggests that mild clinical symptoms could be more frequent in cases of COVID-19 than with SARS-CoV and MERS-CoV [5]. Therefore, the case definition in effect on 24 January lacked sensitivity. This was counter-balanced by a tendency from the infectious diseases specialists in charge of classification of suspected cases to privilege the exposure to Wuhan over the clinical presentation in their decision. However, we cannot exclude that some COVID-19 cases remained undetected in France because of the lack of sensitivity of our case definition. The clinical criteria were expanded on 4 February to include any lower acute respiratory disease and the epidemiological criterion was extended to the whole of China. At that time, the French laboratory capacities were reinforced from one to five laboratories able to perform the diagnostics for COVID-19. Further extension to all 38 referring hospital laboratories is expected by early to mid-February 2020. Santé publique France will deploy in early February the outbreak investigation tool developed by the WHO (Go.Data [6]) in order to facilitate case data management and contact tracing at the national and local level in France.\nContact and co-exposure identification of the three confirmed cases had been initiated as soon as they were classified as possible cases, which facilitated investigations upon confirmation of COVID-19. Confirmation of the diagnosis was made in the evening of 24 January and the investigation to retrieve as exhaustively as possible contacts and co-exposed individuals and evaluate their level of risk of transmission was started immediately overnight. Complete transparency of the investigations was ensured through daily press conferences held by the French health authorities.\nAlthough the follow-up procedure for the contacts/co-exposed persons used in France slightly differ from the ECDC and WHO guidelines [7,8], which were not available at the time of this investigation, it relies on the same general principles. Contact tracing of the passengers seated near Case 1 during the two flights Shanghai–Paris and Paris–Bordeaux was adapted from the ECDC guidelines for infectious diseases transmitted on aircraft [9]. Even though Case 1 was wearing a face mask during those flights, we could not exclude breaches and subsequent risk of transmission to the persons sitting in the two seats around him.\nBecause of the current uncertainties about the capacity of SARS-CoV-2 to easily spread from human to human, the decision to consider a contact as close if the case–contact distance was between 1 m and 2 m was made on a case-by-case basis, depending on the type and length of interaction. Through the extensive interviews made with the cases and their high compliance to cooperate to the investigation, we believe that the contacts most at risk have been satisfactorily identified. All of them could be rapidly contacted and informed about measures to be taken, which they all agreed to. However, some contacts were either impossible to trace back (e.g. co-travellers on public transportation) or evaluated as at negligible risk of exposure because of short and/or distant contacts (e.g. restaurant, contacts with cashiers while running errands, visiting museums), although accidental events carrying the risk of transmission on such occasions, such as an episode of cough of sneezing, cannot be ruled out.\nMoreover, the contact tracing was limited to the period after onset of illness. However, should the transmission of SARS-CoV-2 occur during the asymptomatic phase, we cannot exclude that secondary transmission events initiated from the three confirmed cases remained undetected during the investigations.\nCase 3 developed symptoms 4 days after her husband and 5 days after the couple had left Wuhan. The incubation period of SARS-CoV-2 is currently estimated at around 3–7 days [5,10,11]. Therefore, she may have acquired the infection from her husband, although this cannot be proved.\nThe active surveillance of close contacts of confirmed COVID-19 cases and the implementation of control measures, including home quarantine for those evaluated at moderate/high risk of exposure, decrease the risk of human-to-human transmission originating from imported cases and subsequently delay propagation of the virus in the general population. This allows our healthcare system to prepare for any further spread of the epidemic. Besides, the epidemiological and clinical data collected about the confirmed cases and their contacts will increase our knowledge of COVID-19.\nThe rapid and collaborative management of the first imported COVID-19 cases in France highlights the fact that the French healthcare system is adequately prepared to respond to such emerging diseases threats. However, this surveillance system is extremely time-consuming and requires considerable manpower. The data available on 12 February strongly suggest that human-to-human transmission of SARS-CoV-2 is frequent, with the reproduction number estimated at 2 to 3 [5,10-14]. Twenty-five countries have already reported imported cases from China, and several of them have described autochthonous transmission events [15]. In the case of further spread of SARS-CoV-2 worldwide, it would soon become impossible to detect all imported cases and trace their contacts. Especially the occurrence of large clusters in the same region would strongly impact on the local health authorities’ capacities. The surveillance objectives would then need to evolve from containing the epidemic to mitigating its medical and societal impact.\nAs at 12 February, the contacts of the three first confirmed cases of COVID-19 in France have been followed up for the whole 14 days follow-up time after the cases isolation. No secondary transmission event has been detected so far despite active follow-up. Given the first estimations of the SARS-CoV-2 incubation period, the probability of secondary cases originating from those three cases is negligible."}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T91","span":{"begin":20,"end":28},"obj":"Disease"},{"id":"T92","span":{"begin":132,"end":140},"obj":"Disease"},{"id":"T93","span":{"begin":132,"end":136},"obj":"Disease"},{"id":"T94","span":{"begin":187,"end":195},"obj":"Disease"},{"id":"T95","span":{"begin":429,"end":439},"obj":"Disease"},{"id":"T96","span":{"begin":810,"end":820},"obj":"Disease"},{"id":"T97","span":{"begin":847,"end":880},"obj":"Disease"},{"id":"T98","span":{"begin":882,"end":886},"obj":"Disease"},{"id":"T99","span":{"begin":895,"end":912},"obj":"Disease"},{"id":"T100","span":{"begin":895,"end":904},"obj":"Disease"},{"id":"T101","span":{"begin":919,"end":937},"obj":"Disease"},{"id":"T102","span":{"begin":1265,"end":1284},"obj":"Disease"},{"id":"T103","span":{"begin":1591,"end":1599},"obj":"Disease"},{"id":"T104","span":{"begin":1610,"end":1618},"obj":"Disease"},{"id":"T105","span":{"begin":1610,"end":1614},"obj":"Disease"},{"id":"T106","span":{"begin":1761,"end":1771},"obj":"Disease"},{"id":"T107","span":{"begin":1962,"end":1970},"obj":"Disease"},{"id":"T108","span":{"begin":2143,"end":2162},"obj":"Disease"},{"id":"T109","span":{"begin":2362,"end":2370},"obj":"Disease"},{"id":"T110","span":{"begin":2893,"end":2901},"obj":"Disease"},{"id":"T111","span":{"begin":3673,"end":3683},"obj":"Disease"},{"id":"T112","span":{"begin":3964,"end":3972},"obj":"Disease"},{"id":"T113","span":{"begin":3964,"end":3968},"obj":"Disease"},{"id":"T114","span":{"begin":5027,"end":5035},"obj":"Disease"},{"id":"T115","span":{"begin":5027,"end":5031},"obj":"Disease"},{"id":"T116","span":{"begin":5336,"end":5344},"obj":"Disease"},{"id":"T117","span":{"begin":5336,"end":5340},"obj":"Disease"},{"id":"T118","span":{"begin":5437,"end":5446},"obj":"Disease"},{"id":"T119","span":{"begin":5552,"end":5560},"obj":"Disease"},{"id":"T120","span":{"begin":6066,"end":6074},"obj":"Disease"},{"id":"T121","span":{"begin":6137,"end":6145},"obj":"Disease"},{"id":"T122","span":{"begin":6470,"end":6478},"obj":"Disease"},{"id":"T123","span":{"begin":6470,"end":6474},"obj":"Disease"},{"id":"T124","span":{"begin":6733,"end":6741},"obj":"Disease"},{"id":"T125","span":{"begin":6733,"end":6737},"obj":"Disease"},{"id":"T126","span":{"begin":7172,"end":7180},"obj":"Disease"},{"id":"T127","span":{"begin":7395,"end":7403},"obj":"Disease"},{"id":"T128","span":{"begin":7395,"end":7399},"obj":"Disease"}],"attributes":[{"id":"A91","pred":"mondo_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A92","pred":"mondo_id","subj":"T92","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A93","pred":"mondo_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A94","pred":"mondo_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A95","pred":"mondo_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A96","pred":"mondo_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A97","pred":"mondo_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A98","pred":"mondo_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A99","pred":"mondo_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/MONDO_0005460"},{"id":"A100","pred":"mondo_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A101","pred":"mondo_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/MONDO_0005737"},{"id":"A102","pred":"mondo_id","subj":"T102","obj":"http://purl.obolibrary.org/obo/MONDO_0005087"},{"id":"A103","pred":"mondo_id","subj":"T103","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A104","pred":"mondo_id","subj":"T104","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A105","pred":"mondo_id","subj":"T105","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A106","pred":"mondo_id","subj":"T106","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A107","pred":"mondo_id","subj":"T107","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A108","pred":"mondo_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/MONDO_0005087"},{"id":"A109","pred":"mondo_id","subj":"T109","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A110","pred":"mondo_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A111","pred":"mondo_id","subj":"T111","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A112","pred":"mondo_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A113","pred":"mondo_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A114","pred":"mondo_id","subj":"T114","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A115","pred":"mondo_id","subj":"T115","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A116","pred":"mondo_id","subj":"T116","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A117","pred":"mondo_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A118","pred":"mondo_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A119","pred":"mondo_id","subj":"T119","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A120","pred":"mondo_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A121","pred":"mondo_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A122","pred":"mondo_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A123","pred":"mondo_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A124","pred":"mondo_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A125","pred":"mondo_id","subj":"T125","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A126","pred":"mondo_id","subj":"T126","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A127","pred":"mondo_id","subj":"T127","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A128","pred":"mondo_id","subj":"T128","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Discussion\nSpecific COVID-19 surveillance has been in place in France since 10 January 2020, 3 days after the identification of the SARS-CoV-2 in China. The first three imported cases of COVID-19 in France, the first ones in Europe, were diagnosed 14 days later, on 24 January. Rapid and effective collaboration between the clinicians (general practitioners attending the cases, emergency hotline clinicians (SAMU-centre 15) and infectious diseases specialists), the National Reference Centre and the regional and national health authorities has played a crucial role in the system’s capacity to quickly detect, isolate and investigate those cases in order to implement adequate control measures. The surveillance system as well as the control measures were adapted from those implemented during past emerging infections that occurred after 2003 (severe acute respiratory syndrome (SARS), MERS, influenza A(H1N1)pdm09, Ebolavirus disease), and all involved parties were already familiar with the system, which probably favoured its responsiveness.\nThe case definition of a possible case in use on 24 January was slightly adapted from the one provided by the World Health Organization (WHO), based on an epidemiological link to Wuhan, China and a severe lower acute respiratory disease. It is noteworthy that the first nine possible cases identified in France, including the three confirmed cases described here, displayed mild respiratory symptoms with no sign of severity at the time of diagnosis. Increasing evidence suggests that mild clinical symptoms could be more frequent in cases of COVID-19 than with SARS-CoV and MERS-CoV [5]. Therefore, the case definition in effect on 24 January lacked sensitivity. This was counter-balanced by a tendency from the infectious diseases specialists in charge of classification of suspected cases to privilege the exposure to Wuhan over the clinical presentation in their decision. However, we cannot exclude that some COVID-19 cases remained undetected in France because of the lack of sensitivity of our case definition. The clinical criteria were expanded on 4 February to include any lower acute respiratory disease and the epidemiological criterion was extended to the whole of China. At that time, the French laboratory capacities were reinforced from one to five laboratories able to perform the diagnostics for COVID-19. Further extension to all 38 referring hospital laboratories is expected by early to mid-February 2020. Santé publique France will deploy in early February the outbreak investigation tool developed by the WHO (Go.Data [6]) in order to facilitate case data management and contact tracing at the national and local level in France.\nContact and co-exposure identification of the three confirmed cases had been initiated as soon as they were classified as possible cases, which facilitated investigations upon confirmation of COVID-19. Confirmation of the diagnosis was made in the evening of 24 January and the investigation to retrieve as exhaustively as possible contacts and co-exposed individuals and evaluate their level of risk of transmission was started immediately overnight. Complete transparency of the investigations was ensured through daily press conferences held by the French health authorities.\nAlthough the follow-up procedure for the contacts/co-exposed persons used in France slightly differ from the ECDC and WHO guidelines [7,8], which were not available at the time of this investigation, it relies on the same general principles. Contact tracing of the passengers seated near Case 1 during the two flights Shanghai–Paris and Paris–Bordeaux was adapted from the ECDC guidelines for infectious diseases transmitted on aircraft [9]. Even though Case 1 was wearing a face mask during those flights, we could not exclude breaches and subsequent risk of transmission to the persons sitting in the two seats around him.\nBecause of the current uncertainties about the capacity of SARS-CoV-2 to easily spread from human to human, the decision to consider a contact as close if the case–contact distance was between 1 m and 2 m was made on a case-by-case basis, depending on the type and length of interaction. Through the extensive interviews made with the cases and their high compliance to cooperate to the investigation, we believe that the contacts most at risk have been satisfactorily identified. All of them could be rapidly contacted and informed about measures to be taken, which they all agreed to. However, some contacts were either impossible to trace back (e.g. co-travellers on public transportation) or evaluated as at negligible risk of exposure because of short and/or distant contacts (e.g. restaurant, contacts with cashiers while running errands, visiting museums), although accidental events carrying the risk of transmission on such occasions, such as an episode of cough of sneezing, cannot be ruled out.\nMoreover, the contact tracing was limited to the period after onset of illness. However, should the transmission of SARS-CoV-2 occur during the asymptomatic phase, we cannot exclude that secondary transmission events initiated from the three confirmed cases remained undetected during the investigations.\nCase 3 developed symptoms 4 days after her husband and 5 days after the couple had left Wuhan. The incubation period of SARS-CoV-2 is currently estimated at around 3–7 days [5,10,11]. Therefore, she may have acquired the infection from her husband, although this cannot be proved.\nThe active surveillance of close contacts of confirmed COVID-19 cases and the implementation of control measures, including home quarantine for those evaluated at moderate/high risk of exposure, decrease the risk of human-to-human transmission originating from imported cases and subsequently delay propagation of the virus in the general population. This allows our healthcare system to prepare for any further spread of the epidemic. Besides, the epidemiological and clinical data collected about the confirmed cases and their contacts will increase our knowledge of COVID-19.\nThe rapid and collaborative management of the first imported COVID-19 cases in France highlights the fact that the French healthcare system is adequately prepared to respond to such emerging diseases threats. However, this surveillance system is extremely time-consuming and requires considerable manpower. The data available on 12 February strongly suggest that human-to-human transmission of SARS-CoV-2 is frequent, with the reproduction number estimated at 2 to 3 [5,10-14]. Twenty-five countries have already reported imported cases from China, and several of them have described autochthonous transmission events [15]. In the case of further spread of SARS-CoV-2 worldwide, it would soon become impossible to detect all imported cases and trace their contacts. Especially the occurrence of large clusters in the same region would strongly impact on the local health authorities’ capacities. The surveillance objectives would then need to evolve from containing the epidemic to mitigating its medical and societal impact.\nAs at 12 February, the contacts of the three first confirmed cases of COVID-19 in France have been followed up for the whole 14 days follow-up time after the cases isolation. No secondary transmission event has been detected so far despite active follow-up. Given the first estimations of the SARS-CoV-2 incubation period, the probability of secondary cases originating from those three cases is negligible."}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T118","span":{"begin":42,"end":45},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T119","span":{"begin":542,"end":545},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T120","span":{"begin":553,"end":554},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T121","span":{"begin":905,"end":906},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T122","span":{"begin":1071,"end":1072},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T123","span":{"begin":1171,"end":1183},"obj":"http://purl.obolibrary.org/obo/OBI_0000245"},{"id":"T124","span":{"begin":1244,"end":1245},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T125","span":{"begin":1741,"end":1742},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T126","span":{"begin":3753,"end":3754},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T127","span":{"begin":3755,"end":3759},"obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"T128","span":{"begin":3997,"end":4005},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T129","span":{"begin":4006,"end":4011},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T130","span":{"begin":4038,"end":4039},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T131","span":{"begin":4122,"end":4123},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T132","span":{"begin":5501,"end":5507},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T133","span":{"begin":5713,"end":5718},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T134","span":{"begin":5722,"end":5727},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T135","span":{"begin":5815,"end":5820},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T136","span":{"begin":6322,"end":6331},"obj":"http://www.ebi.ac.uk/efo/EFO_0000876"},{"id":"T137","span":{"begin":6439,"end":6444},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T138","span":{"begin":6448,"end":6453},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T139","span":{"begin":6989,"end":6999},"obj":"http://purl.obolibrary.org/obo/BFO_0000030"},{"id":"T140","span":{"begin":7309,"end":7312},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T141","span":{"begin":7342,"end":7348},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"Discussion\nSpecific COVID-19 surveillance has been in place in France since 10 January 2020, 3 days after the identification of the SARS-CoV-2 in China. The first three imported cases of COVID-19 in France, the first ones in Europe, were diagnosed 14 days later, on 24 January. Rapid and effective collaboration between the clinicians (general practitioners attending the cases, emergency hotline clinicians (SAMU-centre 15) and infectious diseases specialists), the National Reference Centre and the regional and national health authorities has played a crucial role in the system’s capacity to quickly detect, isolate and investigate those cases in order to implement adequate control measures. The surveillance system as well as the control measures were adapted from those implemented during past emerging infections that occurred after 2003 (severe acute respiratory syndrome (SARS), MERS, influenza A(H1N1)pdm09, Ebolavirus disease), and all involved parties were already familiar with the system, which probably favoured its responsiveness.\nThe case definition of a possible case in use on 24 January was slightly adapted from the one provided by the World Health Organization (WHO), based on an epidemiological link to Wuhan, China and a severe lower acute respiratory disease. It is noteworthy that the first nine possible cases identified in France, including the three confirmed cases described here, displayed mild respiratory symptoms with no sign of severity at the time of diagnosis. Increasing evidence suggests that mild clinical symptoms could be more frequent in cases of COVID-19 than with SARS-CoV and MERS-CoV [5]. Therefore, the case definition in effect on 24 January lacked sensitivity. This was counter-balanced by a tendency from the infectious diseases specialists in charge of classification of suspected cases to privilege the exposure to Wuhan over the clinical presentation in their decision. However, we cannot exclude that some COVID-19 cases remained undetected in France because of the lack of sensitivity of our case definition. The clinical criteria were expanded on 4 February to include any lower acute respiratory disease and the epidemiological criterion was extended to the whole of China. At that time, the French laboratory capacities were reinforced from one to five laboratories able to perform the diagnostics for COVID-19. Further extension to all 38 referring hospital laboratories is expected by early to mid-February 2020. Santé publique France will deploy in early February the outbreak investigation tool developed by the WHO (Go.Data [6]) in order to facilitate case data management and contact tracing at the national and local level in France.\nContact and co-exposure identification of the three confirmed cases had been initiated as soon as they were classified as possible cases, which facilitated investigations upon confirmation of COVID-19. Confirmation of the diagnosis was made in the evening of 24 January and the investigation to retrieve as exhaustively as possible contacts and co-exposed individuals and evaluate their level of risk of transmission was started immediately overnight. Complete transparency of the investigations was ensured through daily press conferences held by the French health authorities.\nAlthough the follow-up procedure for the contacts/co-exposed persons used in France slightly differ from the ECDC and WHO guidelines [7,8], which were not available at the time of this investigation, it relies on the same general principles. Contact tracing of the passengers seated near Case 1 during the two flights Shanghai–Paris and Paris–Bordeaux was adapted from the ECDC guidelines for infectious diseases transmitted on aircraft [9]. Even though Case 1 was wearing a face mask during those flights, we could not exclude breaches and subsequent risk of transmission to the persons sitting in the two seats around him.\nBecause of the current uncertainties about the capacity of SARS-CoV-2 to easily spread from human to human, the decision to consider a contact as close if the case–contact distance was between 1 m and 2 m was made on a case-by-case basis, depending on the type and length of interaction. Through the extensive interviews made with the cases and their high compliance to cooperate to the investigation, we believe that the contacts most at risk have been satisfactorily identified. All of them could be rapidly contacted and informed about measures to be taken, which they all agreed to. However, some contacts were either impossible to trace back (e.g. co-travellers on public transportation) or evaluated as at negligible risk of exposure because of short and/or distant contacts (e.g. restaurant, contacts with cashiers while running errands, visiting museums), although accidental events carrying the risk of transmission on such occasions, such as an episode of cough of sneezing, cannot be ruled out.\nMoreover, the contact tracing was limited to the period after onset of illness. However, should the transmission of SARS-CoV-2 occur during the asymptomatic phase, we cannot exclude that secondary transmission events initiated from the three confirmed cases remained undetected during the investigations.\nCase 3 developed symptoms 4 days after her husband and 5 days after the couple had left Wuhan. The incubation period of SARS-CoV-2 is currently estimated at around 3–7 days [5,10,11]. Therefore, she may have acquired the infection from her husband, although this cannot be proved.\nThe active surveillance of close contacts of confirmed COVID-19 cases and the implementation of control measures, including home quarantine for those evaluated at moderate/high risk of exposure, decrease the risk of human-to-human transmission originating from imported cases and subsequently delay propagation of the virus in the general population. This allows our healthcare system to prepare for any further spread of the epidemic. Besides, the epidemiological and clinical data collected about the confirmed cases and their contacts will increase our knowledge of COVID-19.\nThe rapid and collaborative management of the first imported COVID-19 cases in France highlights the fact that the French healthcare system is adequately prepared to respond to such emerging diseases threats. However, this surveillance system is extremely time-consuming and requires considerable manpower. The data available on 12 February strongly suggest that human-to-human transmission of SARS-CoV-2 is frequent, with the reproduction number estimated at 2 to 3 [5,10-14]. Twenty-five countries have already reported imported cases from China, and several of them have described autochthonous transmission events [15]. In the case of further spread of SARS-CoV-2 worldwide, it would soon become impossible to detect all imported cases and trace their contacts. Especially the occurrence of large clusters in the same region would strongly impact on the local health authorities’ capacities. The surveillance objectives would then need to evolve from containing the epidemic to mitigating its medical and societal impact.\nAs at 12 February, the contacts of the three first confirmed cases of COVID-19 in France have been followed up for the whole 14 days follow-up time after the cases isolation. No secondary transmission event has been detected so far despite active follow-up. Given the first estimations of the SARS-CoV-2 incubation period, the probability of secondary cases originating from those three cases is negligible."}
LitCovid-PD-HP
{"project":"LitCovid-PD-HP","denotations":[{"id":"T24","span":{"begin":4871,"end":4876},"obj":"Phenotype"}],"attributes":[{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0012735"}],"text":"Discussion\nSpecific COVID-19 surveillance has been in place in France since 10 January 2020, 3 days after the identification of the SARS-CoV-2 in China. The first three imported cases of COVID-19 in France, the first ones in Europe, were diagnosed 14 days later, on 24 January. Rapid and effective collaboration between the clinicians (general practitioners attending the cases, emergency hotline clinicians (SAMU-centre 15) and infectious diseases specialists), the National Reference Centre and the regional and national health authorities has played a crucial role in the system’s capacity to quickly detect, isolate and investigate those cases in order to implement adequate control measures. The surveillance system as well as the control measures were adapted from those implemented during past emerging infections that occurred after 2003 (severe acute respiratory syndrome (SARS), MERS, influenza A(H1N1)pdm09, Ebolavirus disease), and all involved parties were already familiar with the system, which probably favoured its responsiveness.\nThe case definition of a possible case in use on 24 January was slightly adapted from the one provided by the World Health Organization (WHO), based on an epidemiological link to Wuhan, China and a severe lower acute respiratory disease. It is noteworthy that the first nine possible cases identified in France, including the three confirmed cases described here, displayed mild respiratory symptoms with no sign of severity at the time of diagnosis. Increasing evidence suggests that mild clinical symptoms could be more frequent in cases of COVID-19 than with SARS-CoV and MERS-CoV [5]. Therefore, the case definition in effect on 24 January lacked sensitivity. This was counter-balanced by a tendency from the infectious diseases specialists in charge of classification of suspected cases to privilege the exposure to Wuhan over the clinical presentation in their decision. However, we cannot exclude that some COVID-19 cases remained undetected in France because of the lack of sensitivity of our case definition. The clinical criteria were expanded on 4 February to include any lower acute respiratory disease and the epidemiological criterion was extended to the whole of China. At that time, the French laboratory capacities were reinforced from one to five laboratories able to perform the diagnostics for COVID-19. Further extension to all 38 referring hospital laboratories is expected by early to mid-February 2020. Santé publique France will deploy in early February the outbreak investigation tool developed by the WHO (Go.Data [6]) in order to facilitate case data management and contact tracing at the national and local level in France.\nContact and co-exposure identification of the three confirmed cases had been initiated as soon as they were classified as possible cases, which facilitated investigations upon confirmation of COVID-19. Confirmation of the diagnosis was made in the evening of 24 January and the investigation to retrieve as exhaustively as possible contacts and co-exposed individuals and evaluate their level of risk of transmission was started immediately overnight. Complete transparency of the investigations was ensured through daily press conferences held by the French health authorities.\nAlthough the follow-up procedure for the contacts/co-exposed persons used in France slightly differ from the ECDC and WHO guidelines [7,8], which were not available at the time of this investigation, it relies on the same general principles. Contact tracing of the passengers seated near Case 1 during the two flights Shanghai–Paris and Paris–Bordeaux was adapted from the ECDC guidelines for infectious diseases transmitted on aircraft [9]. Even though Case 1 was wearing a face mask during those flights, we could not exclude breaches and subsequent risk of transmission to the persons sitting in the two seats around him.\nBecause of the current uncertainties about the capacity of SARS-CoV-2 to easily spread from human to human, the decision to consider a contact as close if the case–contact distance was between 1 m and 2 m was made on a case-by-case basis, depending on the type and length of interaction. Through the extensive interviews made with the cases and their high compliance to cooperate to the investigation, we believe that the contacts most at risk have been satisfactorily identified. All of them could be rapidly contacted and informed about measures to be taken, which they all agreed to. However, some contacts were either impossible to trace back (e.g. co-travellers on public transportation) or evaluated as at negligible risk of exposure because of short and/or distant contacts (e.g. restaurant, contacts with cashiers while running errands, visiting museums), although accidental events carrying the risk of transmission on such occasions, such as an episode of cough of sneezing, cannot be ruled out.\nMoreover, the contact tracing was limited to the period after onset of illness. However, should the transmission of SARS-CoV-2 occur during the asymptomatic phase, we cannot exclude that secondary transmission events initiated from the three confirmed cases remained undetected during the investigations.\nCase 3 developed symptoms 4 days after her husband and 5 days after the couple had left Wuhan. The incubation period of SARS-CoV-2 is currently estimated at around 3–7 days [5,10,11]. Therefore, she may have acquired the infection from her husband, although this cannot be proved.\nThe active surveillance of close contacts of confirmed COVID-19 cases and the implementation of control measures, including home quarantine for those evaluated at moderate/high risk of exposure, decrease the risk of human-to-human transmission originating from imported cases and subsequently delay propagation of the virus in the general population. This allows our healthcare system to prepare for any further spread of the epidemic. Besides, the epidemiological and clinical data collected about the confirmed cases and their contacts will increase our knowledge of COVID-19.\nThe rapid and collaborative management of the first imported COVID-19 cases in France highlights the fact that the French healthcare system is adequately prepared to respond to such emerging diseases threats. However, this surveillance system is extremely time-consuming and requires considerable manpower. The data available on 12 February strongly suggest that human-to-human transmission of SARS-CoV-2 is frequent, with the reproduction number estimated at 2 to 3 [5,10-14]. Twenty-five countries have already reported imported cases from China, and several of them have described autochthonous transmission events [15]. In the case of further spread of SARS-CoV-2 worldwide, it would soon become impossible to detect all imported cases and trace their contacts. Especially the occurrence of large clusters in the same region would strongly impact on the local health authorities’ capacities. The surveillance objectives would then need to evolve from containing the epidemic to mitigating its medical and societal impact.\nAs at 12 February, the contacts of the three first confirmed cases of COVID-19 in France have been followed up for the whole 14 days follow-up time after the cases isolation. No secondary transmission event has been detected so far despite active follow-up. Given the first estimations of the SARS-CoV-2 incubation period, the probability of secondary cases originating from those three cases is negligible."}
LitCovid-PD-GO-BP
{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T6","span":{"begin":6503,"end":6515},"obj":"http://purl.obolibrary.org/obo/GO_0000003"}],"text":"Discussion\nSpecific COVID-19 surveillance has been in place in France since 10 January 2020, 3 days after the identification of the SARS-CoV-2 in China. The first three imported cases of COVID-19 in France, the first ones in Europe, were diagnosed 14 days later, on 24 January. Rapid and effective collaboration between the clinicians (general practitioners attending the cases, emergency hotline clinicians (SAMU-centre 15) and infectious diseases specialists), the National Reference Centre and the regional and national health authorities has played a crucial role in the system’s capacity to quickly detect, isolate and investigate those cases in order to implement adequate control measures. The surveillance system as well as the control measures were adapted from those implemented during past emerging infections that occurred after 2003 (severe acute respiratory syndrome (SARS), MERS, influenza A(H1N1)pdm09, Ebolavirus disease), and all involved parties were already familiar with the system, which probably favoured its responsiveness.\nThe case definition of a possible case in use on 24 January was slightly adapted from the one provided by the World Health Organization (WHO), based on an epidemiological link to Wuhan, China and a severe lower acute respiratory disease. It is noteworthy that the first nine possible cases identified in France, including the three confirmed cases described here, displayed mild respiratory symptoms with no sign of severity at the time of diagnosis. Increasing evidence suggests that mild clinical symptoms could be more frequent in cases of COVID-19 than with SARS-CoV and MERS-CoV [5]. Therefore, the case definition in effect on 24 January lacked sensitivity. This was counter-balanced by a tendency from the infectious diseases specialists in charge of classification of suspected cases to privilege the exposure to Wuhan over the clinical presentation in their decision. However, we cannot exclude that some COVID-19 cases remained undetected in France because of the lack of sensitivity of our case definition. The clinical criteria were expanded on 4 February to include any lower acute respiratory disease and the epidemiological criterion was extended to the whole of China. At that time, the French laboratory capacities were reinforced from one to five laboratories able to perform the diagnostics for COVID-19. Further extension to all 38 referring hospital laboratories is expected by early to mid-February 2020. Santé publique France will deploy in early February the outbreak investigation tool developed by the WHO (Go.Data [6]) in order to facilitate case data management and contact tracing at the national and local level in France.\nContact and co-exposure identification of the three confirmed cases had been initiated as soon as they were classified as possible cases, which facilitated investigations upon confirmation of COVID-19. Confirmation of the diagnosis was made in the evening of 24 January and the investigation to retrieve as exhaustively as possible contacts and co-exposed individuals and evaluate their level of risk of transmission was started immediately overnight. Complete transparency of the investigations was ensured through daily press conferences held by the French health authorities.\nAlthough the follow-up procedure for the contacts/co-exposed persons used in France slightly differ from the ECDC and WHO guidelines [7,8], which were not available at the time of this investigation, it relies on the same general principles. Contact tracing of the passengers seated near Case 1 during the two flights Shanghai–Paris and Paris–Bordeaux was adapted from the ECDC guidelines for infectious diseases transmitted on aircraft [9]. Even though Case 1 was wearing a face mask during those flights, we could not exclude breaches and subsequent risk of transmission to the persons sitting in the two seats around him.\nBecause of the current uncertainties about the capacity of SARS-CoV-2 to easily spread from human to human, the decision to consider a contact as close if the case–contact distance was between 1 m and 2 m was made on a case-by-case basis, depending on the type and length of interaction. Through the extensive interviews made with the cases and their high compliance to cooperate to the investigation, we believe that the contacts most at risk have been satisfactorily identified. All of them could be rapidly contacted and informed about measures to be taken, which they all agreed to. However, some contacts were either impossible to trace back (e.g. co-travellers on public transportation) or evaluated as at negligible risk of exposure because of short and/or distant contacts (e.g. restaurant, contacts with cashiers while running errands, visiting museums), although accidental events carrying the risk of transmission on such occasions, such as an episode of cough of sneezing, cannot be ruled out.\nMoreover, the contact tracing was limited to the period after onset of illness. However, should the transmission of SARS-CoV-2 occur during the asymptomatic phase, we cannot exclude that secondary transmission events initiated from the three confirmed cases remained undetected during the investigations.\nCase 3 developed symptoms 4 days after her husband and 5 days after the couple had left Wuhan. The incubation period of SARS-CoV-2 is currently estimated at around 3–7 days [5,10,11]. Therefore, she may have acquired the infection from her husband, although this cannot be proved.\nThe active surveillance of close contacts of confirmed COVID-19 cases and the implementation of control measures, including home quarantine for those evaluated at moderate/high risk of exposure, decrease the risk of human-to-human transmission originating from imported cases and subsequently delay propagation of the virus in the general population. This allows our healthcare system to prepare for any further spread of the epidemic. Besides, the epidemiological and clinical data collected about the confirmed cases and their contacts will increase our knowledge of COVID-19.\nThe rapid and collaborative management of the first imported COVID-19 cases in France highlights the fact that the French healthcare system is adequately prepared to respond to such emerging diseases threats. However, this surveillance system is extremely time-consuming and requires considerable manpower. The data available on 12 February strongly suggest that human-to-human transmission of SARS-CoV-2 is frequent, with the reproduction number estimated at 2 to 3 [5,10-14]. Twenty-five countries have already reported imported cases from China, and several of them have described autochthonous transmission events [15]. In the case of further spread of SARS-CoV-2 worldwide, it would soon become impossible to detect all imported cases and trace their contacts. Especially the occurrence of large clusters in the same region would strongly impact on the local health authorities’ capacities. The surveillance objectives would then need to evolve from containing the epidemic to mitigating its medical and societal impact.\nAs at 12 February, the contacts of the three first confirmed cases of COVID-19 in France have been followed up for the whole 14 days follow-up time after the cases isolation. No secondary transmission event has been detected so far despite active follow-up. Given the first estimations of the SARS-CoV-2 incubation period, the probability of secondary cases originating from those three cases is negligible."}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T122","span":{"begin":0,"end":10},"obj":"Sentence"},{"id":"T123","span":{"begin":11,"end":152},"obj":"Sentence"},{"id":"T124","span":{"begin":153,"end":277},"obj":"Sentence"},{"id":"T125","span":{"begin":278,"end":696},"obj":"Sentence"},{"id":"T126","span":{"begin":697,"end":1047},"obj":"Sentence"},{"id":"T127","span":{"begin":1048,"end":1285},"obj":"Sentence"},{"id":"T128","span":{"begin":1286,"end":1498},"obj":"Sentence"},{"id":"T129","span":{"begin":1499,"end":1636},"obj":"Sentence"},{"id":"T130","span":{"begin":1637,"end":1711},"obj":"Sentence"},{"id":"T131","span":{"begin":1712,"end":1924},"obj":"Sentence"},{"id":"T132","span":{"begin":1925,"end":2065},"obj":"Sentence"},{"id":"T133","span":{"begin":2066,"end":2232},"obj":"Sentence"},{"id":"T134","span":{"begin":2233,"end":2371},"obj":"Sentence"},{"id":"T135","span":{"begin":2372,"end":2474},"obj":"Sentence"},{"id":"T136","span":{"begin":2475,"end":2700},"obj":"Sentence"},{"id":"T137","span":{"begin":2701,"end":2902},"obj":"Sentence"},{"id":"T138","span":{"begin":2903,"end":3152},"obj":"Sentence"},{"id":"T139","span":{"begin":3153,"end":3279},"obj":"Sentence"},{"id":"T140","span":{"begin":3280,"end":3521},"obj":"Sentence"},{"id":"T141","span":{"begin":3522,"end":3721},"obj":"Sentence"},{"id":"T142","span":{"begin":3722,"end":3904},"obj":"Sentence"},{"id":"T143","span":{"begin":3905,"end":4192},"obj":"Sentence"},{"id":"T144","span":{"begin":4193,"end":4385},"obj":"Sentence"},{"id":"T145","span":{"begin":4386,"end":4491},"obj":"Sentence"},{"id":"T146","span":{"begin":4492,"end":4910},"obj":"Sentence"},{"id":"T147","span":{"begin":4911,"end":4990},"obj":"Sentence"},{"id":"T148","span":{"begin":4991,"end":5215},"obj":"Sentence"},{"id":"T149","span":{"begin":5216,"end":5310},"obj":"Sentence"},{"id":"T150","span":{"begin":5311,"end":5399},"obj":"Sentence"},{"id":"T151","span":{"begin":5400,"end":5496},"obj":"Sentence"},{"id":"T152","span":{"begin":5497,"end":5847},"obj":"Sentence"},{"id":"T153","span":{"begin":5848,"end":5932},"obj":"Sentence"},{"id":"T154","span":{"begin":5933,"end":6075},"obj":"Sentence"},{"id":"T155","span":{"begin":6076,"end":6284},"obj":"Sentence"},{"id":"T156","span":{"begin":6285,"end":6382},"obj":"Sentence"},{"id":"T157","span":{"begin":6383,"end":6553},"obj":"Sentence"},{"id":"T158","span":{"begin":6554,"end":6699},"obj":"Sentence"},{"id":"T159","span":{"begin":6700,"end":6841},"obj":"Sentence"},{"id":"T160","span":{"begin":6842,"end":6971},"obj":"Sentence"},{"id":"T161","span":{"begin":6972,"end":7101},"obj":"Sentence"},{"id":"T162","span":{"begin":7102,"end":7276},"obj":"Sentence"},{"id":"T163","span":{"begin":7277,"end":7359},"obj":"Sentence"},{"id":"T164","span":{"begin":7360,"end":7509},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Discussion\nSpecific COVID-19 surveillance has been in place in France since 10 January 2020, 3 days after the identification of the SARS-CoV-2 in China. The first three imported cases of COVID-19 in France, the first ones in Europe, were diagnosed 14 days later, on 24 January. Rapid and effective collaboration between the clinicians (general practitioners attending the cases, emergency hotline clinicians (SAMU-centre 15) and infectious diseases specialists), the National Reference Centre and the regional and national health authorities has played a crucial role in the system’s capacity to quickly detect, isolate and investigate those cases in order to implement adequate control measures. The surveillance system as well as the control measures were adapted from those implemented during past emerging infections that occurred after 2003 (severe acute respiratory syndrome (SARS), MERS, influenza A(H1N1)pdm09, Ebolavirus disease), and all involved parties were already familiar with the system, which probably favoured its responsiveness.\nThe case definition of a possible case in use on 24 January was slightly adapted from the one provided by the World Health Organization (WHO), based on an epidemiological link to Wuhan, China and a severe lower acute respiratory disease. It is noteworthy that the first nine possible cases identified in France, including the three confirmed cases described here, displayed mild respiratory symptoms with no sign of severity at the time of diagnosis. Increasing evidence suggests that mild clinical symptoms could be more frequent in cases of COVID-19 than with SARS-CoV and MERS-CoV [5]. Therefore, the case definition in effect on 24 January lacked sensitivity. This was counter-balanced by a tendency from the infectious diseases specialists in charge of classification of suspected cases to privilege the exposure to Wuhan over the clinical presentation in their decision. However, we cannot exclude that some COVID-19 cases remained undetected in France because of the lack of sensitivity of our case definition. The clinical criteria were expanded on 4 February to include any lower acute respiratory disease and the epidemiological criterion was extended to the whole of China. At that time, the French laboratory capacities were reinforced from one to five laboratories able to perform the diagnostics for COVID-19. Further extension to all 38 referring hospital laboratories is expected by early to mid-February 2020. Santé publique France will deploy in early February the outbreak investigation tool developed by the WHO (Go.Data [6]) in order to facilitate case data management and contact tracing at the national and local level in France.\nContact and co-exposure identification of the three confirmed cases had been initiated as soon as they were classified as possible cases, which facilitated investigations upon confirmation of COVID-19. Confirmation of the diagnosis was made in the evening of 24 January and the investigation to retrieve as exhaustively as possible contacts and co-exposed individuals and evaluate their level of risk of transmission was started immediately overnight. Complete transparency of the investigations was ensured through daily press conferences held by the French health authorities.\nAlthough the follow-up procedure for the contacts/co-exposed persons used in France slightly differ from the ECDC and WHO guidelines [7,8], which were not available at the time of this investigation, it relies on the same general principles. Contact tracing of the passengers seated near Case 1 during the two flights Shanghai–Paris and Paris–Bordeaux was adapted from the ECDC guidelines for infectious diseases transmitted on aircraft [9]. Even though Case 1 was wearing a face mask during those flights, we could not exclude breaches and subsequent risk of transmission to the persons sitting in the two seats around him.\nBecause of the current uncertainties about the capacity of SARS-CoV-2 to easily spread from human to human, the decision to consider a contact as close if the case–contact distance was between 1 m and 2 m was made on a case-by-case basis, depending on the type and length of interaction. Through the extensive interviews made with the cases and their high compliance to cooperate to the investigation, we believe that the contacts most at risk have been satisfactorily identified. All of them could be rapidly contacted and informed about measures to be taken, which they all agreed to. However, some contacts were either impossible to trace back (e.g. co-travellers on public transportation) or evaluated as at negligible risk of exposure because of short and/or distant contacts (e.g. restaurant, contacts with cashiers while running errands, visiting museums), although accidental events carrying the risk of transmission on such occasions, such as an episode of cough of sneezing, cannot be ruled out.\nMoreover, the contact tracing was limited to the period after onset of illness. However, should the transmission of SARS-CoV-2 occur during the asymptomatic phase, we cannot exclude that secondary transmission events initiated from the three confirmed cases remained undetected during the investigations.\nCase 3 developed symptoms 4 days after her husband and 5 days after the couple had left Wuhan. The incubation period of SARS-CoV-2 is currently estimated at around 3–7 days [5,10,11]. Therefore, she may have acquired the infection from her husband, although this cannot be proved.\nThe active surveillance of close contacts of confirmed COVID-19 cases and the implementation of control measures, including home quarantine for those evaluated at moderate/high risk of exposure, decrease the risk of human-to-human transmission originating from imported cases and subsequently delay propagation of the virus in the general population. This allows our healthcare system to prepare for any further spread of the epidemic. Besides, the epidemiological and clinical data collected about the confirmed cases and their contacts will increase our knowledge of COVID-19.\nThe rapid and collaborative management of the first imported COVID-19 cases in France highlights the fact that the French healthcare system is adequately prepared to respond to such emerging diseases threats. However, this surveillance system is extremely time-consuming and requires considerable manpower. The data available on 12 February strongly suggest that human-to-human transmission of SARS-CoV-2 is frequent, with the reproduction number estimated at 2 to 3 [5,10-14]. Twenty-five countries have already reported imported cases from China, and several of them have described autochthonous transmission events [15]. In the case of further spread of SARS-CoV-2 worldwide, it would soon become impossible to detect all imported cases and trace their contacts. Especially the occurrence of large clusters in the same region would strongly impact on the local health authorities’ capacities. The surveillance objectives would then need to evolve from containing the epidemic to mitigating its medical and societal impact.\nAs at 12 February, the contacts of the three first confirmed cases of COVID-19 in France have been followed up for the whole 14 days follow-up time after the cases isolation. No secondary transmission event has been detected so far despite active follow-up. Given the first estimations of the SARS-CoV-2 incubation period, the probability of secondary cases originating from those three cases is negligible."}